News Archive

Complete archive of all Orogen Therapeutics press releases and news articles, listed in chronological order.

Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
Strategic PartnershipJuly 16, 20255 min read

Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries

Strategic partnership combines Chemspace's ultra-large chemical datasets and Enamine's REAL design principles with Orogen's AI-enabled DEL technology to advance next-generation drug discovery.

Read Full Article
Orogen Therapeutics Announces Expansion of Scientific Advisory Board with Drug Discovery and Development Experts
Scientific AdvisoryJune 4, 20255 min read

Orogen Therapeutics Announces Expansion of Scientific Advisory Board with Drug Discovery and Development Experts

Industry leaders Humphrey Gardner and Christopher Winter, PhD join Orogen's expanded SAB as the Company advances its AI-enabled DNA-encoded library platform.

Read Full Article
Orogen Therapeutics Announces Launch of Scientific Advisory Board with AI Drug Discovery Experts
AI & TechnologyMay 21, 20255 min read

Orogen Therapeutics Announces Launch of Scientific Advisory Board with AI Drug Discovery Experts

AI-Drug Discovery leaders Rafael Gómez Bombarelli and Ian Watson join Orogen's SAB as the company advances its AI-enabled DNA-encoded library platform.

Read Full Article
Orogen Therapeutics Announces Expansion of Board with Biopharma Leaders Mikael Dolsten and Dieter Weinand as Independent Non-Executive Directors
GovernanceMay 16, 20255 min read

Orogen Therapeutics Announces Expansion of Board with Biopharma Leaders Mikael Dolsten and Dieter Weinand as Independent Non-Executive Directors

Orogen announces the expansion of its Board of Directors with Independent Non-Executive biopharma leaders Mikael Dolsten, M.D., Ph.D., prior Chief Scientific Officer at Pfizer, and Dieter Weinand, M.S., former CEO of Bayer Pharmaceuticals AG.

Read Full Article
Orogen Therapeutics Announces Expansion of Leadership Team with Appointment of CEO and Senior Medicinal Chemist
LeadershipApril 16, 20255 min read

Orogen Therapeutics Announces Expansion of Leadership Team with Appointment of CEO and Senior Medicinal Chemist

Orogen Therapeutics announces Mark Pykett, PhD, VMD, MBA, as Chief Executive Officer and Dominque Potin, PhD, as Senior Principal Scientist in medicinal chemistry.

Read Full Article
Breakthrough in DNA-Encoded Library Technology Accelerates Drug Discovery Timeline
Research UpdatesApril 15, 20255 min read

Breakthrough in DNA-Encoded Library Technology Accelerates Drug Discovery Timeline

Orogen's FocusDEL™ platform demonstrates significant efficiency gains in identifying novel chemical matter for challenging therapeutic targets.

Read Full Article
Orogen Therapeutics Advances Multiple Programs Toward IND-Enabling Studies
Press ReleasesMarch 28, 20255 min read

Orogen Therapeutics Advances Multiple Programs Toward IND-Enabling Studies

Company's immuno-inflammatory portfolio shows promising preclinical results as lead optimization efforts progress toward clinical development.

Read Full Article
The Future of AI in Drug Discovery: Lessons from DNA-Encoded Libraries
Industry InsightsMarch 10, 20255 min read

The Future of AI in Drug Discovery: Lessons from DNA-Encoded Libraries

Industry analysis explores how AI-enhanced DEL platforms are reshaping pharmaceutical research and development strategies.

Read Full Article
Novel Approaches to Immuno-Inflammatory Disorders: Small Molecules vs. Biologics
PublicationsFebruary 22, 20255 min read

Novel Approaches to Immuno-Inflammatory Disorders: Small Molecules vs. Biologics

Comparative analysis of emerging small molecule therapeutics and their potential advantages over current biological treatments in immune disorders.

Read Full Article

Showing 9 articles

"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."

Mark Pykett

CEO, Orogen Therapeutics